These iRGD exosomes were used to specifically target αvβ3-harboring A549 tumors via delivering the KRAS siRNA in vivo, which resulted in tumor suppression via the knocking down of the KRAS gene [50]. This evidence concerns the gene KRAS and neoplasm.